Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 60% · prior close shown (market closed)
Atrium Therapeutics, Inc. shows decelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue -22% YoY in Q2 FY2026.
2 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
RNA's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on RNA.
Free accounts see more of this; Premium sees all of it.
Reported figures for Atrium Therapeutics, Inc. — research only, not investment advice.
Updated
What happened recently for Atrium Therapeutics, Inc. (RNA) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
RNA's AI investment thesis
Upgrade to Premium for RNA's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$8.42
Market cap
$144.03M
Profitable
No
Revenue $19.64M
Net income
$-16.63M
FY Jul 18, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Atrium Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Atrium Therapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.